drugset

drugset / Trial / NCT01285752

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

NCT01285752 ↗

Phase 2 Completed 240 enrolled Asahi Kasei Therapeutics Corporation

RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.

Timeline

Start: 2011-02
Primary completion: 2012-01
Completion: 2012-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AK-106	Small molecule	—	—

Indications